Rituximab therapy for chronic periaortitis

Annals of the Rheumatic Diseases

Volumn 71, Issue 7, 2012, Pages 1262-1264

  Maritati, Federica ^a   Corradi, Domenico ^b   Versari, Annibale ^c   Casali, Massimiliano ^c   Urban, Maria Letizia ^a   Buzio, Carlo ^a   Vaglio, Augusto ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PREDNISONE; RITUXIMAB; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; AGED; ANAMNESIS; AORTITIS; BACKACHE; BIOPSY TECHNIQUE; CASE REPORT; CHRONIC PERIAORTITIS; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LAPAROSCOPIC BIOPSY; LETTER; MALAISE; MALE; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROPERITONEAL FIBROSIS; TREATMENT OUTCOME;

EID: 84862518070     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201166     Document Type: Letter

References (11)

1. Palmisano A, Vaglio A. Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res Clin Rheumatol 2009;23:339-53.
2. Parums DV. The spectrum of chronic periaortitis. Histopathology 1990;16:423-31.
3. Binder M, Uhl M, Wiech T, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 2012;71:311-12.
4. Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med 2011;154:31-6.
5. Corradi D, Maestri R, Palmisano A, et al. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int 2007;72:742-53.
6. Vaglio A, Manenti L, Allegri L, et al. ANCA-positive periaortic vasculitis: does it fall within the spectrum of vasculitis? J Intern Med 2002;251:268-71.
7. Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011;378:338-46.
8. Zaidan M, Cervera-Pierot P, de Seigneux S, et al. Evidence of follicular T-cell implication in a case of IgG4-related systemic disease with interstitial nephritis. Nephrol Dial Transplant 2011;26:2047-50.
9. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
10. Vaglio A, Palmisano A, Ferretti S, et al. Peripheral inflammatory arthritis in patients with chronic periaortitis: report of five cases and review of the literature. Rheumatology (Oxford) 2008;47:315-18.
11. Martorana D, Vaglio A, Greco P, et al. Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. Arthritis Rheum 2006;55:126-30.